MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

Jyotika Varshney, Subbaya Subramanian

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.

Original languageEnglish (US)
Article number31
JournalFrontiers in Molecular Biosciences
Issue numberJUN
StatePublished - Jun 17 2015

Bibliographical note

Publisher Copyright:
© 2015 Varshney and Subramanian.


  • Bone sarcoma
  • MicroRNAs
  • Osteosarcoma
  • Pediatric oncology
  • Sarcoma
  • Soft tissue sarcoma
  • Therapeutics


Dive into the research topics of 'MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics'. Together they form a unique fingerprint.

Cite this